Puzolcabtagene Autoleucel

普基奥仑赛

Report date: 2026/01/12 17:47:06

Base Information

Drug NamePuzolcabtagene Autoleucel
Drug Alias NamepCAR-19B细胞自体回输制剂Priscabtagene Autoleucel普基仑赛普利得凯pCAR-19B
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Original Approved Country/TerritoryMainland China
Original Approved Date2025/11/04
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChongqing Precision Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChongqing Precision Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A